Abbreviation Key: c = chicken; GH = growth hormone; IGF = insulin-like growth factor; IGFBP = insulin-like growth factor binding proteins. 
INTRODUCTION
Growth hormone (GH) is required for normal development of chickens. Serum growth hormone is first detectable on Day 12 of embryonic development but remains under 10 ng/mL until Day 20 of incubation (Kikuchi et al., 1991) . Growth hormone receptors and signal transduction mechanisms are developed during the latter embryonic stages, starting on about Day 12 (Kuhn et al., 1986; Berghman et al., 1989; Porter et al., 1995) . The circulating concentration of GH has been positively correlated with growth rate in early posthatch chickens (Burke and Marks, 1982) . Moreover, plasma GH decreases as growth rate declines with posthatch age (Vasilatos-Younken and Zarkower, 1987; VasilatosYounken et al., 1990) . On the other hand, slower growing chickens display higher circulating concentrations of GH than faster growing chickens (Burke and Marks, 1982; Stewart and Washburn, 1983; Goddard et al., 1988) .
When growth in chickens is retarded by hypophysectomy or when endogenous GH is low, growth can be stimulated by posthatch administration of mammalian GH . Additionally, growth rate of intact birds was reduced by antisera against chicken GH (Scanes, 1987) . Although there are some exceptions (Myers and Peterson, 1974; Scanes et al., 1975; , mammalian GH generally has been ineffective in stimulating growth rate, efficiency of gain, or organ growth in the normal growing chicken during either early or late posthatch periods (Scanes et al., 1975; Tojo et al., 1978) . Furthermore, chicken (c) GH (pituitary derived or recombinant) does not substantially or consistently improve growth performance variables in the early posthatch period when administered by injection or chronic infusion Bowen et al., 1987; McGuinness and Cogburn, 1988; Peebles et al., 1988; Cogburn et al., 1989) .
Growth hormone is the most important hormone for normal postnatal longitudinal bone growth. Exogenous GH increased long (predominantly cortical bone) bone growth in normal (Jorgensen et al., 1991; Andreassen and Oxlund, 1996) , dwarf (Wright et al., 1995; Martinez et al., 1996) , ovariectomized (Andreassen and Oxlund, 1996; Noland et al., 1996) , and hypophysectomized rats (Schiltz et al., 1992) , whereas no significant effect on cancellous bone mass was seen (Jorgensen et al., 1991) . Furthermore, these results were supported in GHtransgenic mice with a very high concentration of GH (Ohlsson et al., 1996) and in old female monkeys injected with 100 mg GH/kg per d for 7 wk (Sass et al., 1997) . In the chicken, there is evidence that exogenous mammalian GH stimulates tibial growth of chicks during embryonic development (Hsieh et al., 1952; Blumenthal et al., 1954) . Additionally, demonstrated that in ovo administration of ovine GH on Day 11 of embryonic development increased subsequent shank length of 7-wk-old male broilers. Although systemic GH administration increased circulating concentrations of other hormones that influence bone such as insulin-like growth factor (IGF)-I and the active vitamin D metabolite (Goff et al., 1990; Klindt et al., 1996) , GH stimulated bone formation via direct interaction with bone tissue (Baker et al., 1992; Hedner et al., 1996) . Growth hormone stimulated the proliferation of osteoblasts and the differentiated function of these cells, such as type I collagen synthesis, osteocalcin expression, and alkaline phosphatase activity in primary isolated rat (Ernst and Froesch, 1988 ) and chicken osteosarcoma cell culture (Slootweg et al., 1988) . Increased cortical bone growth often has been associated with increased mechanical strength of whole bone as a function of both the mineral and the matrix (primarily type I collagen fibrils) constituents (Martin and Ishida, 1989; Shah et al., 1995) .
In ovo injections of either ovine or porcine GH increased posthatch growth in male broilers and ovine GH improved feed efficiency in male broilers . However, whether exogenous cGH in ovo has any influence on chicken embryonic or later posthatch growth has remained unresolved. Additionally, differences between chicken and mammalian GH sequences (Leung et al., 1984) may result in variations in bioactivity. Therefore, the objective of this work was to administer cGH in ovo and then measure its effect on growth, feed efficiency, and biomechanical properties of cortical bone development of chickens.
MATERIALS AND METHODS

Hatching Eggs
Fertilized eggs (Hubbard × Hubbard) were obtained from the West Virginia University Poultry Facilities. Eggs (30 eggs per cGH treatment and 15 eggs per control group) were injected once on one of the following Days: 1, 4, or 7 through 18 of incubation (total 630 eggs).
Injection Procedure
In ovo administration of 100 mL of either pituitary derived cGH or vehicle (0.03 M NaHCO 3 , 0.15 M NaCl, pH 8.3) per egg was performed through the blunt end of the eggs. Pituitary derived cGH was diluted in vehicle at 100 ng/100 mL and was stored at -20 C. Prior to injection, the blunt end of the egg was sterilized with 70% ethanol. A single hole was created with a dental drill bit without penetrating the chorioallantoic membrane. Both cGH (100 ng per egg) and vehicle were injected into the albumen with a 22-gauge needle. The hole was sealed with an adhesive sticker. Eggs were set in a Buckeye incubator/ hatcher 2 (temperature 37 ± 0.5 C, humidity 86 to 87%).
Pen Assignment and Experimental Design
At hatching, chicks were vaccinated for Marek's Disease (s.c. in the neck; 0.2 cc per chick) and separated by feather sexing. All chicks in a treatment group were assigned to a randomly selected pen (n = 6 to 29 per pen, a total of 28 pens).
During the first 3 wk, chicks were fed a starter ration that contained 21.2% CP and 3,080 kcal ME/kg. Birds had free access to feed and water. During the last 3 wk of production, birds were fed a grower ration that contained 19.5% CP and 3,124 kcal ME/kg. Chicks were housed in a thermostatically controlled building with a 24-h lighting schedule.
Pen weight and mortality were recorded weekly. Average feed consumption and feed to gain ratios per pen were determined weekly. At the end of the growth period (42 d of age), treatment groups were selected for further analysis according to feed efficiency and live weight gain. Day 1, 11, 15 and 16 treatment groups (n = 5 to 6 birds per treatment group), as well as associated control groups (n = 4 to 6 per control group) for a total of 9 to 12 chicks per treatment day were selected for further processing. Whole body, breast muscle (both breasts and rib cage), liver, heart, and leg (leg and thigh) data were collected. Individual tissue or organ weights were recorded.
Texture Analysis
Pectoralis profundus was removed from each chick and cooked to 80 C internal temperature on a Farberware Smokeless Indoor Grill. 3 Right or left sides were randomly chosen. A Beckman Industrial Datalogger 4 was used to monitor internal cooking temperature. To determine percentage cook yield, raw and cooked weights were recorded. After cooked muscle was cooled to room temperature, 1.27 cm-thick slices were cut perpendicular to the fiber orientation of the muscle and two or three 1.27-cm-diameter cores were removed from each strip (Kenney et al., 1996) . An Instron Universal Testing Machine, 5 equipped with a Warner-Bratzler shear force attachment (Model 1520.50) 6 was used for shear force determination. Warner-Bratzler shear force was determined by a crosshead speed of 127 mm/min. Output was recorded via a Daytronic main frame equipped with a LVDT conditioner (Model 9130), 6 and output from the main frame was sent to a computer with a DT 2805 acquisition board. 7
Bone Biomechanical Parameters
One leg from each chicken was exarticulated at random at the hip joint and kept frozen until bone measurements were taken. Samples were thawed overnight at 2 C. The tibias were dissected free by removing all muscle tissues, periost, and fibula. Tibias were subjected to three-point bending tests until failure under displacement control (127 mm/min) using a servo Instron Universal Testing Machine. Tests were conducted at room temperature and specimens were kept moist during testing. Span length was 60 mm throughout the experiment and the load was applied at the midpoint of the shaft in antero-posterior direction. A load cell (Model 152 A.50) 6 with a maximum capacity of 500 N was used to measure the applied load and the maximum value of the load was recorded as failure load (F). After failure, cortical bone thickness (t) and cross-sectional diameter were measured on two perpendicular axes (a and b; Figure 1 ) at the fracture site using a caliper. Assuming the bone as a uniform hollow elliptical beam, cross-sectional area (A) and moment of inertia (I xx ) were calculated as structural parameters of resistance (Martin, 1991; 1993) using the following equations (Gere and Timoshenko, 1990) :
Assuming that material properties are uniformly distributed along the beam, maximum moment (M) and bending strength (ultimate breaking strength) (s) were calculated as (Gere and Timoshenko, 1990) 
where L is the span length.
Ash Weight and Collagen Analysis
Following mechanical testing, bones were cut into 0.5-to 1-cm strips using a band saw and subsequently frozen in liquid nitrogen. Frozen samples were powdered in a prechilled stainless steel Waring blender. 8 Approximately 4 to 6 mg of each duplicate bone powder sample was transferred to weighed dry crucibles. Dry weight was determined following heating to constant weight at 110 C for 2 h. Ash weight was determined following overnight heating at 600 C in a muffled furnace and expressed as percentage of dry bone weight. Hydroxyproline concentration was measured by the method of Monnier et al., (1986) as an indicator of collagen content. Briefly, 40 mg of duplicate powdered bone sample was delipidated overnight in a chloroform:methanol (2:1) solution. Samples were then rehydrated in 50% methanol and hydrolyzed in 6 N HCl at 110 C for 18 h. Prior to capping for heating, N 2 was used to flush all tubes. Following hydrolysis, the samples were evaporated in a Speed Vac centrifuge vacuum drier. 9 Subsequently, samples were reconstituted in 250 mL distilled H 2 O and filtered using a Costar ® Spin-X ® centrifuge tube filter. 10 Samples were analyzed for hydroxyproline concentrations at 564 nm wavelength using a Shimadzu spectrophotometer (Model UV-1201). 11
Statistical Analysis
Analysis of variance was performed by the GLM procedures of SAS ® (SAS Institute, 1989) as a three-factor factorial arrangement of treatments in a completely random design. A previous experiment indicated that the variance among chicks within a pen was a valid estimate of experimental error. The Least Significant Difference test was used to compare the means. The CATMOD test was used to compare hatchability. Statements of significance were based on P < 0.05 unless otherwise noted. 
RESULTS
There were no significant differences in hatchability between control and cGH treatment groups on any injection day (Table 1) . However, injection of either cGH or vehicle on Day 1 or 4 of incubation compared to other injection days reduced hatchability (P < 0.05; Table 1 ).
Measurements of Growth Performance
In ovo administration of cGH on Day 15 or 16 of incubation increased body weight of female broilers (P < 0.01; Figure 2 ), whereas body weights of male broilers were increased by Day 1 treatment (P < 0.04; Figure 2 ). Pooled mean cumulative feed conversion ratio of all treatment groups at the end of the treatment period was improved compared to their respective control groups (for cGH treated groups: 1.81 ± 0.02, for control groups: 1.9 ± 0.03; P < 0.05). As there were no significant differences either among the treatment groups or among the control groups in terms of feed conversion ratios, values were represented as pooled means.
Breast weights of female broilers from treatment groups Day 15 or 16 were increased (P < 0.01, P < 0.05 respectively; Table 2 ). On the other hand, breast weights of male broilers were not altered significantly by in ovo administration of cGH on any given injection day (Table  2) . Liver weights of female broilers from treatment Day 15 were increased (P < 0.01; Figure 2 ). In contrast, in ovo administration of cGH on Day 11 of incubation increased liver weights of male broilers (P < 0.03; Figure 2 ). There were no significant differences between control and treatment groups on any single injection day in terms of heart and leg weights other than sex effects (Table 2) . Warner-Bratzler shear force ratios on P. profundus muscle between treatment and control groups were not different on any given injection day.
Bone Analysis
In ovo administration of cGH on Day 11 or Day 16 increased hydroxyproline concentration and crosssectional area of female broiler tibias (P < 0.05, Table 3 ). This increase was associated with a reduction in the ultimate breaking strength (stress) of female broiler tibias from the same groups (P < 0.05; Table 3 ); however, there was no significant difference in male broiler tibias for these measurements (Table 3) . In ovo administration of cGH did not alter percentage ash, tibia density, weight, length, cortical bone thickness and breaking force of tibias on any given injection day (Table 3) .
DISCUSSION
A single in ovo administration of cGH increased body weight and tissue development of 42-d-old broilers, although the magnitude of the responses were different between male and female broilers. Feed conversion ratios of all in ovo cGH injected mixed-sex broilers were improved significantly compared to their respective control groups. Although the specific mechanism of GH TABLE 2. Effects of in ovo chicken growth hormone (cGH) administration on heart, leg, and breast weights of 42-d-old broilers (x ± SEM, n = 5 to 6 for each treatment and control group) **P < 0.01, *P < 0.05, compared to their respective control groups within the same sex. 1 M = male; F = female; OH-proline = hydroxyproline; *P < 0.05 compared to respective control group within same sex. action resulting in these various responses in male and female broilers is unknown, partial explanations for the observed findings could be due to sexual-dimorphism, altered thyroid function, and IGF-I and insulin-like growth factor binding proteins (IGFBP) function and expression. Thyroid hormone metabolism has been linked to the regulation of GH action and the growth process of chickens (Singh et al., 1968; Scanes, 1987) . The thyroid is functional early in embryonic development and becomes pituitary dependent at Day 10 to 12 of embryogenesis (Thommes and Jameson, 1980) . Moreover, GH regulates thyroxine secretion in growing chickens and regulates the circulating concentration of triiodothyronine in adult chickens and embryos by inducing 5′-monodeiodinase activity inside the liver cell (Kuhn et al., 1986; Darras et al., 1990) . Thus, it is possible that exogenous GH in this study had the effect of modifying thyroid hormone secretion.
Insulin-like growth factor-I is required for normal growth in chickens (Proudman et al., 1994) . In a previous study, we demonstrated that in ovo administration of recombinant human IGF-I (100 ng per embryo) altered body weights and tissue development of 42-d-old broilers (Kocamis et al., 1998) . Unlike mammalian cell culture, avian growth plate chondrocytes from birds of different ages do not respond to the addition of GH to the culture medium in terms of IGF-I concentrations (Rosselot et al., 1994) . Additionally, the effect of GH on IGF-I is not consistent although exogenous studies have demonstrated GH to either increase (Leung et al., 1986; Vasilatos-Younken et al., 1990) or be without effect on IGF-I in the circulation (Cogburn et al., 1989; Rosselot et al., 1995) in avian species. During chicken embryonic development, IGF-I gene expression is GH-independent (Kikuchi et al., 1991; Tanaka et al., 1996) . However, IGF-I gene expression in bone tissue is not GH-dependent either before or after hatching (Tanaka et al., 1996) . For this reason, the influence of in ovo administration of IGF-I during embryonic development on postnatal long bone growth is under investigation in our laboratory.
There are six distinct classes of IGFBP found in extracellular fluid and serum of mammals, termed IGFBP-1 through IGFBP-6 (Hill, 1996) . The bioactivity of IGF, particularly in bone tissue, is modulated by these IGFBP. For example, mRNA for IGFBP-5, which is a stimulatory IGFBP for osteoblast proliferation (Bautista et al., 1991) , was increased twofold after GH treatment of primary rat osteoblasts (McCarthy et al., 1994) . However, only IGFBP-2 (Schoen et al., 1995) and IGFBP-5 (Allander et al., 1995) have been isolated in chicken serum. It is not known whether these IGFBP in chicken are similar in function to those in mammals. It has been suggested that GH may regulate circulating concentrations of chicken IGFBP (Scanes, 1997) . Therefore, whether increased concentrations of circulating GH during embryonic development of the chicken has any effect on specific type of IGFBP could be of interest.
There is a sexual dimorphism between growth and GH concentrations in chickens. Some evidence implicates testosterone in the physiological control of GH secretion (Harvey et al., 1979) . Also, during the early (0 to 3 wk) posthatch period, male broilers grow faster, have larger body size, and display higher circulating GH concentrations than females (Leung et al., 1987; Vasilatos-Younken et al., 1990) . However, there is no sex difference in hepatic binding of GH for broiler chickens at Day 1 of age or during the late posthatch period (Leung et al., 1987) . These studies could, to some extent, explain the varying response of in ovo injection of GH during different days of incubation between the male and female.
In ovo administration of cGH on Day 11 or 16 of incubation resulted in a greater response in the biomechanical properties of the tibias of female broilers. For example, cross-sectional areas and hydroxyproline concentrations of these bones were significantly increased. However, their ultimate breaking strength ratios were reduced, indicating that increased bone mass was not associated with strength. There was no significant effect on percentage ash ratio, tibia length, weight, density, cortical bone thickness, or breaking force ratios found on any given day of injection. These results could be due, in part, to the changes in moisture content, bone cell number, collagen cross-linking, circulating levels of other hormones such as the active vitamin D metabolite, and bone turnover.
Chorioallantoic injections of GH (5 mg per embryo) on Day 13 of incubation and continued every other day for 5 d increased hatch weights and tibial growth of chickens (Hsieh et al., 1952) . In that study, female chicks were more sensitive to GH than were their male counterparts. In contrast, showed that in ovo administration of ovine GH (250 mg per embryo) on Day 11 of incubation resulted in a greater response in male broilers. In our study, we did not find a significant effect of in ovo cGH on this day for any measures of growth other than increased weight of the male liver. Additionally, there was no significant difference between treated and control groups in terms of hatch weight of broilers. As chicken GH (100 ng per embryo) was administered to embryos from Hubbard × Hubbard broiler strains in this study, these variations in response could be due to the differences in the type of GH, dosage, and genetic line of the broilers.
Warner-Bratzler shear force ratios between in ovoinjected treatment and control groups were not different on any given injection day in this study. Likewise, we reported earlier that in ovo administration of recombinant human IGF-I did not alter shear force ratios in either male or female broilers (Kocamis et al., 1998) . Therefore, in ovo administration of cGH or recombinant human IGF-I does not detract from product quality.
In conclusion, in ovo administration of cGH on Day 1 (males) and Day 15 or 16 (females) of embryonic development increased body weights and altered tissue development of 42-d-old broilers. Increased body weights of female broilers from treatment groups Day 15 or Day 16 were associated with increased breast weights. Moreover, feed conversion ratios of all treatment groups were increased significantly compared to their respective control groups. In ovo administration of cGH on Day 11 or 16 of incubation increased hydroxyproline concentration and cross-sectional area of the tibia from female broilers. There was no significant difference between treatment and control groups in terms of Warner-Bratzler shear force on any given injection day. Therefore, in ovo administration of cGH on specific days may provide a means of increasing broiler growth rate and efficiency without altering quality of the products.
